DESTINY GASTRIC 03

Research code: DESTINY GASTRIC 03
Research name:  Phase 1b/2, multicenter, open-label, dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of trastuzumab deruxtecan (T-DXd) as monotherapy or in combination in adult participants with gastric cancer expressing HER2 (DESTINY-Gastric03)

Indication: gastric cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Study population:  In monotherapy or in combination therapy in adult participants with HER2-expressing gastric cancer (DESTINY-Gastric03) 

Investigated drug: Trastuzumab deruxtecan